

AMENDMENTS TO THE CLAIMS

Claims 1-4 (Previously canceled)

Claim 5. (Currently amended) An immunoassay of a human medullasin comprising immobilizing human medullasin in a test sample by sandwiching said human medullasin between an anti-human medullasin monoclonal antibody immobilized on an insoluble carrier and a labeled anti-human medullasin monoclonal antibody by antigen-antibody reactions to form a complex, said anti-human medullasin monoclonal antibody is at least one selected from a group consisting of designated 3F03, 3G03, 2E04 and 1G12; and quantifying said label in said complex.

Claim 6. (Previously added) The immunoassay of a human medullasin according to claim 5, where said anti-human medullasin monoclonal antibody specifically recognizes human medullasin.

Claim 7. (Previously added) The immunoassay of a human medullasin according to claim 5, where said anti-human medullasin monoclonal antibody belongs to immunoglobulin class IgG.

Claim 8. (Previously added) The immunoassay of a human medullasin according to claim 5, where said anti-human medullasin monoclonal antibody is originated from a mouse.

Claim 9. (Previously added) The immunoassay of a human medullasin according to claim 5, where said anti-human medullasin monoclonal antibody is obtained by culturing hybridomas prepared by cell fusion between antibody-producing cells recovered from a mouse immunized with human medullasin and myeloma cells, and recovering an anti-human medullasin monoclonal antibody which specifically recognizes human medullasin from the culture in which said hybridomas are cultured.